Neuroblastoma: MIBG Imaging and New Tracers

Area of Science:

• Nuclear Medicine
• Pediatric Oncology
• Radiology

Background:

• Neuroblastoma, an embryonic peripheral sympathetic nervous system tumor, has a high relapse rate (nearly 50%) and poor long-term survival (<40%).
• Accurate staging via radiological and nuclear medicine imaging is essential for optimal therapeutic strategies in neuroblastoma.

Purpose of the Study:

• To discuss therapeutic strategies for primary and follow-up diagnosis of neuroblastoma.
• To evaluate the role of metaiodobenzylguanidine (MIBG) scintigraphy, novel positron emission tomography (PET) tracers, and multimodality imaging in neuroblastoma management.

Main Methods:

• Review of MIBG scintigraphy, a tumor-specific imaging agent targeting the norepinephrine transporter.
• Exploration of advanced PET tracers to overcome MIBG's limitations (e.g., resolution, sensitivity, acquisition time).
• Emphasis on integrating morphological imaging with nuclear medicine for comprehensive pre-operative and biopsy planning.

Main Results:

• MIBG imaging, while tumor-specific, suffers from limitations in spatial resolution, sensitivity for small lesions, and delayed results.
• PET imaging offers potential to overcome many limitations of MIBG scintigraphy.
• Multimodality imaging, combining functional and morphological data, is indispensable for precise neuroblastoma staging and treatment planning.

Conclusions:

• Advanced imaging techniques, including novel PET tracers and multimodality approaches, are crucial for improving neuroblastoma diagnosis and follow-up.
• These methods enhance staging accuracy, potentially leading to more effective therapeutic choices and improved patient outcomes.